Skip to main content

Published locations for FDA approves oral TYK2 inhibitor deucravacitinib for treating psoriasis

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. FDA approves oral TYK2 inhibitor deucravacitinib for treating psoriasis

User login

  • Reset your password
  • /content/fda-approves-oral-tyk2-inhibitor-deucravacitinib-treating-psoriasis
  • /clinicianreviews/article/257760/psoriasis/fda-approves-oral-tyk2-inhibitor-deucravacitinib-treating
  • /edermatologynews/article/257760/psoriasis/fda-approves-oral-tyk2-inhibitor-deucravacitinib-treating
  • /familypracticenews/article/257760/psoriasis/fda-approves-oral-tyk2-inhibitor-deucravacitinib
  • /fedprac/article/257760/psoriasis/fda-approves-oral-tyk2-inhibitor-deucravacitinib-treating-psoriasis
  • /internalmedicinenews/article/257760/psoriasis/fda-approves-oral-tyk2-inhibitor-deucravacitinib
  • /rheumatologynews/article/257760/psoriasis/fda-approves-oral-tyk2-inhibitor-deucravacitinib-treating
  • /rheumatology/article/257760/psoriasis/fda-approves-oral-tyk2-inhibitor-deucravacitinib-treating
  • /internalmedicine/article/257760/psoriasis/fda-approves-oral-tyk2-inhibitor-deucravacitinib-treating
  • /dermatology/article/257760/psoriasis/fda-approves-oral-tyk2-inhibitor-deucravacitinib-treating
  • /familymedicine/article/257760/psoriasis/fda-approves-oral-tyk2-inhibitor-deucravacitinib-treating
  • /emergencymedicine/article/257760/psoriasis/fda-approves-oral-tyk2-inhibitor-deucravacitinib-treating
  • /psoriatic-arthritis-icymi/article/257760/psoriasis/fda-approves-oral-tyk2-inhibitor-deucravacitinib